Atypical Metastatic Disease in Thyroid from Pancreatic Neuroendocrine Tumor and its Response to [¹⁷⁷Lu]Lu-DOTATATE Peptide Receptor Radionuclide Therapy (PRRT): A Promising Therapeutic Option for Somatostatin Receptor Expressing Unusual Metastatic Sites

Abstract

There are no standardized treatment guidelines for this condition with atypical sites of metastatic disease in neuroendocrine tumors (NETs). We present a patient of pancreatic NET with liver metastasis and incidentally detected thyroid gland metastasis, a rare site of metastasis in the context of NETs. After two cycles of [¹⁷⁷Lu]Lu-DOTATATE peptide receptor radionuclide therapy (PRRT), the metastatic thyroid lesion exhibited a remarkable response, as evidenced by neck ultrasonography and post-PRRT single photon emission computed tomography/computed tomography scan. This case upholds the fact that PRRT can demonstrate an excellent response at the atypical metastatic sites, thereby avoiding the necessity for surgical treatment and preventing morbidity associated with other therapeutic options.

Keywords

[¹⁷⁷Lu]Lu-DOTATATE - peptide receptor radionuclide therapy (PRRT) - neuroendocrine tumors (NET) - thyroid metastasis - atypical metastatic sites

Publikationsverlauf

Artikel online veröffentlicht:
26. Juni 2025

• References

• 1 Battistella E, Pomba L, Mattara G, Franzato B, Toniato A. Metastases to the thyroid gland: review of incidence, clinical presentation, diagnostic problems and surgery, our experience. J Endocrinol Invest 2020; 43 (11) 1555-1560
• 2 Priyadarshini S, Allison DB, Chauhan A. Comprehensive assessment of somatostatin receptors in various neoplasms: a systematic review. Pharmaceutics 2022; 14 (07) 1394
• 3 Khessib T, Khessib S, Berry G, Aparici M. Neuroendocrine metastasis to the thyroid from unknown primary and extrathyroidal disease response to peptide receptor radionuclide therapy. Radiol Case Rep 2023; 18 (11) 3945-3948
• 4 Sivrikoz E, Ozbey NC, Kaya B. et al. Neuroendocrine tumors presenting with thyroid gland metastasis: a case series. J Med Case Rep 2012; 6: 73
• 5 Massani M, Caratozzolo E, Bridda A. et al. Isolated thyroidal metastasis as primary manifestation of pancreatic neuroendocrine carcinoma. Pancreas 2010; 39 (07) 1113-1114
• 6 Zhang Y, Lin B, Lu KN. et al. Neuroendocrine neoplasm with metastasis to the thyroid: a case report and literature review. Front Oncol 2023; 13: 1024908
• 7 Parghane RV, Basu S. 177 Lu-DOTATATE PRRT for multiple unusual metastatic sites in neuroendocrine tumor. Clin Nucl Med 2022; 47 (10) 874-875